All In Biotech

Drug Trial Radar · NCT06081348

Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Sep 16, 2024

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Holland Bloorview Kids Rehabilitation HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Azrieli Foundation (Funder); Canadian Institutes of Health Research (Funder); Ontario Brain Institute (Funder); McMaster University; Western University; Queen's University; University of Alberta; Alberta Health services; St. Justine's Hospital; Dalhousie University; Unity Health Toronto; University of Toronto; The Hospital for Sick Children; Maternal, Infant, Child and Youth Research Network (MICYRN)
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 8 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.

Conditions

  • Neurodevelopmental Disorders
  • Autism
  • Autism Spectrum Disorder
  • Fragile X Syndrome
  • Tuberous Sclerosis
  • 22Q11 Deletion Syndrome
  • 22Q11 Deletion
  • ADHD
  • Tic Disorders
  • Tourette Syndrome
  • Tourette Syndrome in Children
  • Tourette Syndrome in Adolescence
  • ADHD - Combined Type
  • ADHD Predominantly Inattentive Type
  • ADHD, Predominantly Hyperactive - Impulsive
  • Anxiety
  • Anxiety Disorders

Interventions

  • SertralineDrug

    Oral capsule (25mg, 50mg, 100mg, 200mg)

  • PlaceboOther

    Oral placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Screen for Child Anxiety Related Emotional Disorders (SCARED) - parent versionTime frame: 16 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Alberta Children's Hospital - University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • University of Alberta-Glenrose

    Edmonton, Alberta, Canada · Recruiting

  • Dalhousie University - IWK Health Centre

    Halifax, Nova Scotia, Canada · Active not recruiting

  • McMaster University

    Hamilton, Ontario, Canada · Recruiting

  • Queen's University

    Kingston, Ontario, Canada · Recruiting

  • University of Western Ontario, Lawson Health Research Institute

    London, Ontario, Canada · Recruiting

  • Holland Bloorview Kids Rehabilitation Hospital

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.